Sinopharm BIBP — Competitive Intelligence Brief

Sinopharm BIBP (Sinopharm BIBP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated viral vaccine SARS-CoV-2 spike protein and other viral antigens Immunology / Infectious Disease Biologic

Target snapshot

Sinopharm BIBP (Sinopharm BIBP) — Vaxxinity, Inc.. Sinopharm BIBP is a COVID-19 inactivated vaccine that stimulates immune responses against SARS-CoV-2 by presenting inactivated viral particles to the immune system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sinopharm BIBP TARGET	Sinopharm BIBP	Vaxxinity, Inc.	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
Inactivated SARS-CoV-2 Vaccine (Vero cell）	Inactivated SARS-CoV-2 Vaccine (Vero cell）	Sinovac Research and Development Co., Ltd.	marketed	inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
COVAX only (1st and 2nd dose)	COVAX only (1st and 2nd dose)	China National Biotec Group Company Limited	marketed	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
CoronaVac Vaccine	CoronaVac Vaccine	Clover Biopharmaceuticals AUS Pty	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
CoronaVac Biofarma COVID-19 Vaccine	CoronaVac Biofarma COVID-19 Vaccine	Dr. Soetomo General Hospital	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Inactivated SARS-CoV-2 vaccine	Inactivated SARS-CoV-2 vaccine	Jiangsu Province Centers for Disease Control and Prevention	phase 3	Inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine class)

1. Sinovac Biotech Co., Ltd · 9 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 9 drugs in this class
3. GlaxoSmithKline · 5 drugs in this class
4. Valneva Austria GmbH · 4 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Centers for Disease Control and Prevention · 3 drugs in this class
7. China National Biotec Group Company Limited · 2 drugs in this class
8. Statens Serum Institut · 2 drugs in this class
9. Institute of Medical Biology, Chinese Academy of Medical Sciences · 2 drugs in this class
10. Crucell Holland BV · 2 drugs in this class